PSP Research LLC Buys New Position in Alumis Inc. $ALMS

PSP Research LLC bought a new stake in shares of Alumis Inc. (NASDAQ:ALMS) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 43,769 shares of the company’s stock, valued at approximately $427,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its stake in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after buying an additional 4,894 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Alumis by 173.7% in the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after buying an additional 7,467 shares during the period. CWM LLC boosted its stake in shares of Alumis by 1,028.7% in the 3rd quarter. CWM LLC now owns 10,384 shares of the company’s stock valued at $41,000 after buying an additional 9,464 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Alumis by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after buying an additional 979 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Alumis by 104.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company’s stock valued at $47,000 after buying an additional 6,027 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ALMS shares. Stifel Nicolaus started coverage on Alumis in a research note on Wednesday, February 25th. They issued a “buy” rating and a $44.00 price objective for the company. Loop Capital set a $37.00 price objective on Alumis in a research note on Wednesday, January 21st. Morgan Stanley reiterated an “overweight” rating and issued a $39.00 price objective on shares of Alumis in a research note on Friday. Guggenheim lifted their price objective on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday. Finally, Wells Fargo & Company lifted their price objective on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $40.30.

More Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Chardan Capital raised its price target on Alumis to $40 from $38 and kept a Buy rating, signaling strong upside potential for the stock. Chardan price target raise via Benzinga
• Positive Sentiment: HC Wainwright lifted several earnings estimates for Alumis, including Q2 2026, Q3 2026, Q4 2026, FY2026, and FY2027, which suggests modestly improving expectations for the business. HC Wainwright estimate updates
• Neutral Sentiment: HC Wainwright maintained a Neutral rating with a $25 price target, which is less bullish than Chardan’s view and may temper enthusiasm. HC Wainwright coverage
• Neutral Sentiment: Recent research coverage and forecast updates appear to be the main catalyst, rather than any new operational announcement or clinical update from Alumis. Alumis consensus estimates
• Negative Sentiment: Despite the analyst support, Alumis continues to be expected to report losses across 2026 and 2027, so fundamental profitability remains a risk factor for the stock. Alumis earnings estimates

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $21.52 on Wednesday. Alumis Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $30.60. The firm has a market capitalization of $2.74 billion, a PE ratio of -10.87 and a beta of -0.31. The stock’s 50-day simple moving average is $24.20 and its 200-day simple moving average is $19.31.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The business had revenue of $1.74 million for the quarter, compared to analyst estimates of $2.10 million. On average, sell-side analysts forecast that Alumis Inc. will post -2.89 earnings per share for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.